fda compounding semaglutide crackdown news november 2025 How Crackdowns Are Affecting GLP-1 Use In September 2, 2025: U.S. compounding

If you are like me and find that your medical insurance doesn't cover medical weight loss medications, your only option is to pay out of pocket

Overall sales grew modestly (~1% nominal, ~2% ex-FX) versus 2024

Keep those two ideas separate when comparing vial contents, injection details, or online dose charts

caloric restriction during growth periods can affect final adult height, and whether orforglipron's appetite-suppressing effects would impair normal growth trajectories requires dedicated study

Dehydration is another overlooked factor

Semaglutide, marketed as Wegovy, functions solely as a GLP-1 receptor agonist and typically produces weight loss ranging from 10% to 15% of body weight